Ágnes Benedict, MSc, MA, Senior Research Leader and Executive Director, Modeling & Simulation, Health Economics Center at Evidera.

Ágnes Benedict

MSc, MA, Executive Director, EMC Scientific Affairs, Senior Research Leader, Evidence Synthesis, Modeling & Communication

Based in Evidera’s Budapest office, Agi directs economic evaluation projects, including advanced modeling studies, burden of illness studies, and modeling studies. She has worked on several advanced post hoc statistical analyses of trial data to better understand the impact of treatment. She also led several studies investigating the relative effectiveness of products using novel indirect comparisons techniques. Agi has developed submissions, including cost-effectiveness analyses for international economic submission to respective authorities in England, the Netherlands, Scotland, and many other European countries, and also for Australia. She has been involved in designing a utility study and collecting health state utilities in the UK. She has worked in several areas of oncology, including metastatic colorectal cancer, renal cell carcinoma, breast cancer, multiple myeloma, and beyond. She also has experience working in the areas of rheumatoid arthritis, depression, and cardiovascular disease.

Agi is also interested in policy issues. She is a co-chair of the Special Interest Group in Oncology Modeling of the International Society of PharmacoEconomics and Outcomes Research. She conducted analyses of pharmaceutical reimbursement policies and submission guidelines in selected European countries and researched the origins of the UK and international cost-effectiveness thresholds.

Agi holds a BS in economics; a Master’s degree in public economics from the Budapest University of Economic Sciences, Hungary; and a Master’s in health economics from the University of York, UK, as well as a postgraduate certificate of statistics from the University of Sheffield, UK. She has presented studies at international conferences and is the co-author of abstracts and manuscripts that have appeared in the British Journal of Cancer, BJU International, Expert Opinion in Pharmacotherapy, International Journal of Clinical Practice, Journal of Affective Disorder, and Pharmacoeconomics.